91 episodes

PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

PeerVoice Oncology & Haematology Video PeerVoice

    • Science

PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

    • video
    Novel Therapies for Patients With DLBCL: What Does the Future Hold?

    Novel Therapies for Patients With DLBCL: What Does the Future Hold?

    Go online to peervoice.com/VYU860 to view the entire programme with slides. After completing “Novel Therapies for Patients With DLBCL: What Does the Future Hold?”, participants will be able to: Explain the rationale for novel therapeutic options for patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL); Evaluate the risk-benefit profiles of current and emerging therapies for the management of R/R DLBCL; and Incorporate available data on the use of novel anti-CD19 antibody strategies to treat R/R DLBCL into clinical practice.

    • 1 hr 5 min
    • video
    New Targets in Heart Failure: Congress Updates on SGLT2 Inhibitors

    New Targets in Heart Failure: Congress Updates on SGLT2 Inhibitors

    Go online to peervoice.com/QTK860 to view the entire programme with slides. After completing “New Targets in Heart Failure: Congress Updates on SGLT2 Inhibitors”, participants will be able to: Explain the rationale for SGLT2 inhibition in patients with heart failure (HF); Analyse clinical evidence for safety and efficacy of medical therapy such as SGLT2 inhibitors in patients with HF; and Describe the potential clinical implications of novel strategies on outcomes in HF.

    • 19 min
    • video
    Mapping New Blueprints for Lung Cancer Care: Congress Updates in NSCLC and ES-SCLC

    Mapping New Blueprints for Lung Cancer Care: Congress Updates in NSCLC and ES-SCLC

    Go online to peervoice.com/ZFC860 to view the entire programme with slides. After completing “Mapping New Blueprints for Lung Cancer Care: Congress Updates in NSCLC and ES-SCLC”, participants will be able to: Evaluate the latest evidence for the adjuvant treatment of EGFR-mutated non-small-cell lung cancer (NSCLC); and Outline key updates on the use of immunotherapy in the management of extensive-stage small cell lung cancer (ES-SCLC).

    • 16 min
    • video
    Wake Up and Smell the Coffee: Kicking Into Play Novel Treatment Options for Nasal Polyposis

    Wake Up and Smell the Coffee: Kicking Into Play Novel Treatment Options for Nasal Polyposis

    Go online to peervoice.com/GPA860 to view the entire programme with slides. After completing “Wake Up and Smell the Coffee: Kicking Into Play Novel Treatment Options for Nasal Polyposis”, participants will be able to: Summarise the benefits and limitations associated with standard of care treatment options for managing nasal polyposis in patients with chronic rhinosinusitis; Analyse recent clinical trial data associated with current and emerging biologic therapies for the management of patients with chronic rhinosinusitis and nasal polyposis; and Develop individualised treatment plans for patients with chronic rhinosinusitis and nasal polyposis who are eligible for add-on biologic therapy.

    • 21 min
    • video
    Clearing the Path Forward for Cancer-Associated VTE Treatment: The Role of Direct Oral Anticoagulants in Canadian Practice

    Clearing the Path Forward for Cancer-Associated VTE Treatment: The Role of Direct Oral Anticoagulants in Canadian Practice

    Go online to peervoice.com/RGZ860 to view the entire programme with slides. After completing “Clearing the Path Forward for Cancer-Associated VTE Treatment: The Role of Direct Oral Anticoagulants in Canadian Practice”, participants will be able to: Discuss the latest evidence with direct oral anticoagulants (DOACs) for the management of cancer-associated venous thromboembolism (VTE); and Outline optimal clinical use of DOACs in cancer-associated VTE, based on the data and recent guideline recommendations.

    • 20 min
    • video
    The Evolving Role of AR-Targeted Agents in Prostate Cancer: A Window of Opportunity to Maximize Outcomes

    The Evolving Role of AR-Targeted Agents in Prostate Cancer: A Window of Opportunity to Maximize Outcomes

    Go online to peervoice.com/YJF860 to view the entire programme with slides. After completing “The Evolving Role of AR-Targeted Agents in Prostate Cancer: A Window of Opportunity to Maximize Outcomes”, participants will be able to: Identify the clinical implications of the most recent data evaluating androgen receptor (AR)-targeted agents in metastatic castration-sensitive prostate cancer (mCSPC); Define which patients with mCSPC should be considered for treatment with AR-targeted agents; and Formulate a therapeutic treatment plan for patients with prostate cancer on AR-targeted agents that balances efficacy and safety.

    • 8 min

Top Podcasts In Science

Listeners Also Subscribed To

More by PeerVoice